24/7 Market News Snapshot 06 October, 2025 – Invivyd, Inc. Common Stock (NASDAQ:IVVD)

October 6, 2025

DENVER, Colo., 06 October, 2025 (www.247marketnews.com) – (NASDAQ:IVVD) are discussed in this article.
Invivyd, Inc. (IVVD) is currently witnessing a remarkable surge in its stock price, reflecting keen investor interest as it opens at $1.295 and trades at $1.420, marking an increase of 22.41% from the previous day’s close of $1.160. The trading volume has surged to 1.73 million shares, indicating robust market activity and positive sentiment surrounding the company.

This surge is further bolstered by a significant announcement from Invivyd, which has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. This approval allows the company to commence two crucial clinical trials: the DECLARATION and LIBERTY trials, both aimed at assessing the safety and efficacy of their novel monoclonal antibody candidate, VYD2311, in the fight against COVID-19.

The DECLARATION trial is designed as a Phase 3 randomized, placebo-controlled study targeting symptomatic COVID-19 prevention, set to enroll approximately 2,000 participants. It will compare the effectiveness of a single dose versus monthly dosing to enhance individualized protection strategies. Scheduled to begin around the end of 2025, the study anticipates reporting top-line results by mid-2026.

Additionally, the LIBERTY trial will focus on evaluating VYD2311’s safety and tolerability in conjunction with existing mRNA vaccines, enrolling around 300 participants to examine the potential benefits of co-administration. With commercial quantities of VYD2311 already available, Invivyd is committed to offering alternative solutions for individuals, particularly those at higher risk.

Reflecting on the company’s mission, Marc Elia, Chairman of Invivyd’s Board of Directors, emphasized the importance of empowering individuals with diverse protective options tailored to their specific health needs. As developments unfold, further insights into the REVOLUTION program and these trials will be disclosed at an upcoming public investor event, signaling a promising trajectory for Invivyd and its stakeholders.

Related news for (IVVD)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.